Cargando…

Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25‐Year Nationwide Cohorts

BACKGROUND: Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) share many histopathologic and clinical features. Whether they are parts of a one‐disease continuum has been discussed. METHODS AND RESULTS: We compared medical record data of 351 CS and 28 GCM cases diagnosed in Finland since the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordenswan, Hanna‐Kaisa, Lehtonen, Jukka, Ekström, Kaj, Räisänen‐Sokolowski, Anne, Mäyränpää, Mikko I., Vihinen, Tapani, Miettinen, Heikki, Kaikkonen, Kari, Haataja, Petri, Kerola, Tuomas, Rissanen, Tuomas T., Kokkonen, Jorma, Alatalo, Aleksi, Pietilä‐Effati, Päivi, Utriainen, Seppo, Kupari, Markku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174201/
https://www.ncbi.nlm.nih.gov/pubmed/33660520
http://dx.doi.org/10.1161/JAHA.120.019415
_version_ 1783702856276115456
author Nordenswan, Hanna‐Kaisa
Lehtonen, Jukka
Ekström, Kaj
Räisänen‐Sokolowski, Anne
Mäyränpää, Mikko I.
Vihinen, Tapani
Miettinen, Heikki
Kaikkonen, Kari
Haataja, Petri
Kerola, Tuomas
Rissanen, Tuomas T.
Kokkonen, Jorma
Alatalo, Aleksi
Pietilä‐Effati, Päivi
Utriainen, Seppo
Kupari, Markku
author_facet Nordenswan, Hanna‐Kaisa
Lehtonen, Jukka
Ekström, Kaj
Räisänen‐Sokolowski, Anne
Mäyränpää, Mikko I.
Vihinen, Tapani
Miettinen, Heikki
Kaikkonen, Kari
Haataja, Petri
Kerola, Tuomas
Rissanen, Tuomas T.
Kokkonen, Jorma
Alatalo, Aleksi
Pietilä‐Effati, Päivi
Utriainen, Seppo
Kupari, Markku
author_sort Nordenswan, Hanna‐Kaisa
collection PubMed
description BACKGROUND: Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) share many histopathologic and clinical features. Whether they are parts of a one‐disease continuum has been discussed. METHODS AND RESULTS: We compared medical record data of 351 CS and 28 GCM cases diagnosed in Finland since the late 1980s and followed until February 2018 for a composite end point of cardiac death, aborted sudden death, and heart transplantation. Heart failure was the presenting manifestation in 50% versus 15% (P<0.001), and high‐grade atrioventricular block in 21% versus 43% (P=0.044), of GCM and CS, respectively. At presentation, left ventricular ejection fraction was ≤50% in 81% of cases of GCM versus in 48% of CS (P=0.004). The median (interquartile range) of plasma NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) was 5273 (2782–11309) ng/L on admission in GCM versus 859 (290–1950) ng/L in CS (P<0.001), and cardiac troponin T exceeded 50 ng/L in 17 of 19 cases of GCM versus in 48 of 239 cases of CS (P<0.001). The 5‐year estimate of event‐free survival was 77% (95% CI, 72%–82%) in CS versus 27% (95% CI, 10%–45%) in GCM (P<0.001). By Cox regression analysis, GCM predicted cardiac events with a hazard ratio of 5.16 (95% CI, 2.82–9.45), which, however, decreased to 1.58 (95% CI, 0.71–3.52) after inclusion of markers of myocardial injury and dysfunction in the model. CONCLUSIONS: GCM differs from CS in presenting with more extensive myocardial injury and having worse long‐term outcome. Yet the key determinant of prognosis appears to be the extent of myocardial injury rather than the histopathologic diagnosis.
format Online
Article
Text
id pubmed-8174201
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81742012021-06-11 Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25‐Year Nationwide Cohorts Nordenswan, Hanna‐Kaisa Lehtonen, Jukka Ekström, Kaj Räisänen‐Sokolowski, Anne Mäyränpää, Mikko I. Vihinen, Tapani Miettinen, Heikki Kaikkonen, Kari Haataja, Petri Kerola, Tuomas Rissanen, Tuomas T. Kokkonen, Jorma Alatalo, Aleksi Pietilä‐Effati, Päivi Utriainen, Seppo Kupari, Markku J Am Heart Assoc Original Research BACKGROUND: Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) share many histopathologic and clinical features. Whether they are parts of a one‐disease continuum has been discussed. METHODS AND RESULTS: We compared medical record data of 351 CS and 28 GCM cases diagnosed in Finland since the late 1980s and followed until February 2018 for a composite end point of cardiac death, aborted sudden death, and heart transplantation. Heart failure was the presenting manifestation in 50% versus 15% (P<0.001), and high‐grade atrioventricular block in 21% versus 43% (P=0.044), of GCM and CS, respectively. At presentation, left ventricular ejection fraction was ≤50% in 81% of cases of GCM versus in 48% of CS (P=0.004). The median (interquartile range) of plasma NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) was 5273 (2782–11309) ng/L on admission in GCM versus 859 (290–1950) ng/L in CS (P<0.001), and cardiac troponin T exceeded 50 ng/L in 17 of 19 cases of GCM versus in 48 of 239 cases of CS (P<0.001). The 5‐year estimate of event‐free survival was 77% (95% CI, 72%–82%) in CS versus 27% (95% CI, 10%–45%) in GCM (P<0.001). By Cox regression analysis, GCM predicted cardiac events with a hazard ratio of 5.16 (95% CI, 2.82–9.45), which, however, decreased to 1.58 (95% CI, 0.71–3.52) after inclusion of markers of myocardial injury and dysfunction in the model. CONCLUSIONS: GCM differs from CS in presenting with more extensive myocardial injury and having worse long‐term outcome. Yet the key determinant of prognosis appears to be the extent of myocardial injury rather than the histopathologic diagnosis. John Wiley and Sons Inc. 2021-03-04 /pmc/articles/PMC8174201/ /pubmed/33660520 http://dx.doi.org/10.1161/JAHA.120.019415 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Nordenswan, Hanna‐Kaisa
Lehtonen, Jukka
Ekström, Kaj
Räisänen‐Sokolowski, Anne
Mäyränpää, Mikko I.
Vihinen, Tapani
Miettinen, Heikki
Kaikkonen, Kari
Haataja, Petri
Kerola, Tuomas
Rissanen, Tuomas T.
Kokkonen, Jorma
Alatalo, Aleksi
Pietilä‐Effati, Päivi
Utriainen, Seppo
Kupari, Markku
Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25‐Year Nationwide Cohorts
title Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25‐Year Nationwide Cohorts
title_full Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25‐Year Nationwide Cohorts
title_fullStr Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25‐Year Nationwide Cohorts
title_full_unstemmed Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25‐Year Nationwide Cohorts
title_short Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25‐Year Nationwide Cohorts
title_sort manifestations and outcome of cardiac sarcoidosis and idiopathic giant cell myocarditis by 25‐year nationwide cohorts
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174201/
https://www.ncbi.nlm.nih.gov/pubmed/33660520
http://dx.doi.org/10.1161/JAHA.120.019415
work_keys_str_mv AT nordenswanhannakaisa manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT lehtonenjukka manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT ekstromkaj manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT raisanensokolowskianne manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT mayranpaamikkoi manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT vihinentapani manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT miettinenheikki manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT kaikkonenkari manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT haatajapetri manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT kerolatuomas manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT rissanentuomast manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT kokkonenjorma manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT alataloaleksi manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT pietilaeffatipaivi manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT utriainenseppo manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts
AT kuparimarkku manifestationsandoutcomeofcardiacsarcoidosisandidiopathicgiantcellmyocarditisby25yearnationwidecohorts